RUO Disclaimer: All QRM products are strictly for in vitro laboratory and research use only by qualified researchers in appropriate facilities. Nothing here implies, suggests, or recommends any diagnostic, therapeutic, or clinical application or use in humans or animals.
- SSL Secured
- Secure Checkout
- Guaranteed Delivery
- Third-Party Tested
GLP2 (TZ)
A dual-acting incretin peptide studied for its simultaneous engagement of GLP-1 and GIP receptors. Among the most actively researched compounds in metabolic signaling today.
Price range: $90.00 through $200.00
- +99% Purity
- Third-Party Tested
- COA Available
- SSL Secured
- Secure Checkout
- Guaranteed Delivery
- Third-Party Tested
A dual-acting incretin peptide studied for its simultaneous engagement of GLP-1 and GIP receptors. Among the most actively researched compounds in metabolic signaling today.
About GLP2 (TZ)
GLP2 (TZ) was developed from research examining the complementary roles of two distinct incretin hormones in metabolic regulation. GLP-1 and GIP are both secreted in response to nutrient intake, but act through separate receptor systems with overlapping and, in some respects, distinct downstream effects. GIP, or glucose-dependent insulinotropic polypeptide, had long been characterized for its insulinotropic properties, though its role in adipose tissue metabolism and energy balance had remained an active area of mechanistic investigation. GLP2 (TZ) was designed to engage both receptor systems simultaneously, providing researchers with a tool for studying how co-activation of these pathways influences metabolic outcomes relative to single-receptor agonism.
The primary research profile of GLP2 (TZ) reflects the biological breadth of dual incretin receptor engagement. Studies have examined its effects on appetite signaling, fat mass, lean mass, glycemic control, and a range of cardiometabolic markers, with investigators using both single-receptor comparators and mechanistic designs to parse the contributions of each pathway. Research interest has centered in part on the GIP receptor’s expression in adipose tissue and its potential role in fat depot regulation, an area of activity that is absent from GLP-1 receptor agonism and that researchers have studied as a distinguishing feature of GLP2 (TZ)’s metabolic profile.
GLP2 (TZ) occupies a well-defined position in the incretin research landscape as the compound that extended the single-agonist framework established by earlier GLP-1 receptor agonists. Its research profile has informed ongoing investigation into how incretin pathway combinations influence metabolic biology, and it continues to serve as a comparative reference point as the field advances toward compounds with broader multi-receptor activity. Researchers have studied GLP2 (TZ) both as a standalone subject and as a methodological anchor for understanding what dual-receptor engagement adds to the mechanistic picture established by single-agonist predecessors.
Mechanism of Action
- Dual GLP-1 and GIP Receptor Agonism: GLP2 (TZ) has been studied for its capacity to bind and activate both the GLP-1 receptor and the GIP receptor, two G protein-coupled receptors with overlapping but distinct expression patterns and downstream signaling profiles. Research has examined how simultaneous engagement of both receptors influences the magnitude and character of incretin-mediated signaling relative to selective single-receptor agonism.
- Complementary Appetite and Satiety Signaling: GLP-1 receptor activation is well characterized for its effects on hypothalamic appetite centers and vagal satiety pathways. GIP receptor signaling has been investigated for its own contributions to central and peripheral energy balance regulation. Studies have examined how co-activation of both pathways in GLP2 (TZ) influences overall appetite signaling and caloric intake behavior in research models.
- Adipose Tissue GIP Receptor Activity: GIP receptors are expressed on adipocytes, and research has investigated their role in fat storage, lipid mobilization, and adipose tissue metabolism. GLP2 (TZ) has been studied for the degree to which its GIP receptor component engages these adipose-specific pathways, with investigators examining changes in fat depot composition and lipid dynamics as distinct research endpoints.
- Glucose-Dependent Insulin Secretion via Dual Pathways: Both GLP-1 and GIP receptors mediate glucose-dependent insulin secretion from pancreatic beta cells. GLP2 (TZ) has been investigated for the cumulative insulinotropic effect of activating both receptors simultaneously, with research examining how dual-pathway stimulation influences postprandial insulin dynamics, glucose clearance, and glycemic variability.
- Energy Expenditure and Metabolic Rate Investigations: Research has examined whether dual-receptor engagement in GLP2 (TZ) produces measurable effects on basal metabolic rate and energy expenditure beyond those attributable to changes in caloric intake. Investigators have studied this dimension to better characterize the relative contributions of intake reduction and energy utilization to the compound’s observed metabolic profile.
Research Highlights
GLP2 (TZ) was built on a straightforward but significant research insight: if one incretin receptor produces meaningful metabolic effects, engaging two simultaneously should tell researchers something that single-receptor studies never could. Studies have used receptor-selective comparators to characterize exactly what the GIP component adds to the picture, establishing GLP2 (TZ) as the compound that moved incretin research beyond the single-pathway framework.
GLP2 (TZ) is studied for how two distinct satiety signals, GLP-1 and GIP receptor activation, interact when triggered at the same time. Research has examined whether the GIP component contributes a mechanistically separate appetite signal on top of the well-characterized GLP-1 pathway, and what that combination means for caloric intake behavior in research models.
One of the most distinctive aspects of GLP2 (TZ) research is the GIP receptor's expression on adipocytes, a dimension of activity entirely absent from GLP-1 receptor agonism. Studies have examined how this direct adipose-level engagement influences fat depot dynamics and lipid signaling, making GLP2 (TZ) the first compound in this class to investigate metabolic outcomes at both the satiety and fat-cell level simultaneously.
GLP2 (TZ) has been positioned head-to-head against GLP-1 receptor agonists across multiple research designs, generating one of the most direct comparative datasets in incretin research. These studies have built a translational framework for understanding what dual-receptor engagement adds at both the mechanistic and outcome level, establishing GLP2 (TZ) as the field's reference point for everything that comes after it.
Product Specifications
- Molecular Formula
- C₂₂₅H₃₄₈N₄₈O₆₈
- Molecular Weight
- 4813.47 g/mol
- CAS #
- 2023788-19-2
- Sequence
- Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-NH₂
- Purity
- ≥99% (HPLC verified)
- Form
- Lyophilized powder
- Appearance
- White to off-white powder
- Solubility
- Universal Solvent
- Storage
- -20°C (lyophilized), 2-8°C (after preparation)
Reference
- Jastreboff, A.M., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. https://doi.org/10.1056/NEJMoa2206038
- Frias, J.P., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. https://doi.org/10.1056/NEJMoa2107519
- Coskun, T., et al. (2022). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism, 18, 3-14. https://doi.org/10.1016/j.molmet.2018.09.009
Related Products
GLP3 (RT)
Lyophilized Powder
Price range: $100.00 through $175.00
- Third Party Tested
- ≥99% Purity
